Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | IDO1 | P14902 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 4/20 | 0.64 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.61 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.61 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.61 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 4/20 | 0.61 |
| ▸ | CA2 | P00918 | 4/20 | 0.61 |
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA9 | Q16790 | 3/20 | 0.61 |
| ▸ | MMP1 | P03956 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31500695 | 0.95 | KMT2A (0.66) | PKMKMT2AMEN1GAALMNA | |
| Acedapsone SCHEMBL152710 | 0.91 | PKM (0.85) | PKMKMT2AMEN1GAACYP2C19 | |
| Acedapsone SCHEMBL22518385 | 0.89 | PKM (0.82) | PKMKMT2AMEN1GAACYP2C19 | |
| Acedapsone SCHEMBL28716352 | 0.89 | PKM (0.82) | PKMKMT2AMEN1GAACYP2C19 | |
| SCHEMBL2615418 | 0.87 | KMT2A (0.81) | KMT2AMEN1GAALMNACYP2C19 | |
| SCHEMBL1753885 | 0.87 | KMT2A (0.81) | KMT2AMEN1GAALMNACYP2C19 | |
| Hydrochloric Acid SCHEMBL30443411 | 0.85 | KMT2A (0.78) | KMT2AMEN1GAALMNACYP2C19 | |
| SCHEMBL23620238 | 0.84 | PKM (1.00) | PKMKMT2AMEN1GAALMNA | |
| SCHEMBL19392261 | 0.84 | PKM (0.74) | PKMKMT2AGAACYP2C19POLB | |
| SCHEMBL11297179 | 0.84 | PKM (0.74) | PKMKMT2AMEN1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060121489-A1 | High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-06-08 | — | — | US | claimed |
| US-20020055530-A1 | Compositions and methods for promoting tissue regeneration | URI HERZBERG | 2002-05-09 | — | — | US | claimed |
| WO-2001076592-A1 | COMPOSITIONS AND METHODS FOR PROMOTING NEURAL REGENERATION | ACORDA THERAPEUTICS, INC. (US) | 2001-10-18 | — | — | WO | claimed |
| US-6290929-B1 | ARYLALDEHYDE 5-OXO-1,2,4-TRIAZINE HYDRAZIDE DERIVATIVE. | THE PROCTER & GAMBLE COMPANY | 2001-09-18 | — | — | US | claimed |
| EP-0102476-B1 | METHOD OF MODULATING THE IMMUNE RESPONSE SYSTEM IN MAMMALS | AMERICAN CYANAMID COMPANY (US) | 1986-11-05 | — | — | EP | claimed |
| EP-0102476-A1 | Method of modulating the immune response system in mammals | AMERICAN CYANAMID COMPANY (US) | 1984-03-14 | — | — | EP | claimed |
| US-20180318217-A1 | Liposomal Curcumin for Treatment of Diseases | SIGNPATH PHARMA INC. | 2018-11-08 | — | — | US | disclosed |
| US-10004687-B2 | Liposomal curcumin for treatment of diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-06-26 | — | — | US | disclosed |
| US-20140322303-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-30 | — | — | US | disclosed |
| US-8784881-B2 | Liposomal curcumin for treatment of diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140024617-A1 | TREATMENT OF CANCER WITH COMPLEX ORGANIC-INORGANIC PIGMENT COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-01-23 | — | — | US | disclosed |
| US-8563595-B2 | Treatment of cancer with complex organic-inorganic pigment compositions | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-10-22 | — | — | US | disclosed |
| US-20100125098-A1 | TREATMENT OF CANCER WITH COMPLEX ORGANIC-INORGANIC PIGMENT COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-05-20 | — | — | US | disclosed |
| US-20020055530-A1 | Compositions and methods for promoting tissue regeneration | URI HERZBERG | 2002-05-09 | — | — | US | disclosed |
| WO-2001076592-A1 | COMPOSITIONS AND METHODS FOR PROMOTING NEURAL REGENERATION | ACORDA THERAPEUTICS, INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| EP-0394542-A1 | Bone marrow cell recovery with synthetic csf inducers | AMERICAN CYANAMID COMPANY (US) | 1990-10-31 | — | — | EP | disclosed |
| US-4965284-A | IMMUNOMODULATORS | AMERICAN CYANAMID COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| EP-0342433-A2 | Substituted dibenzothiaphenes | AMERICAN CYANAMID COMPANY (US) | 1989-11-23 | — | — | EP | disclosed |
| US-4532349-A | 2-Amino-4'(phenylsulfonyl) acetanilides | AMERICAN CYANAMID COMPANY (US) | 1985-07-30 | — | — | US | disclosed |
| EP-0102476-A1 | Method of modulating the immune response system in mammals | AMERICAN CYANAMID COMPANY (US) | 1984-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125098-A1 | TREATMENT OF CANCER WITH COMPLEX ORGANIC-INORGANIC PIGMENT COMPOSITIONS | TYR, SLCO2A1, SLCO4C1 | PKM 1197/4885KMT2A 1913/4885MEN1 555/4885 |
| US-20020055530-A1 | Compositions and methods for promoting tissue regeneration | TST, DCX, GAP43 | PKM 2328/4885KMT2A 4017/4885MEN1 4760/4885 |
| US-20140322303-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF DISEASES | LIPA, LPCAT3, LCLAT1 | PKM 3022/4885KMT2A 2082/4885MEN1 255/4885 |
| US-20140024617-A1 | TREATMENT OF CANCER WITH COMPLEX ORGANIC-INORGANIC PIGMENT COMPOSITIONS | TYR, SLCO2A1, SLCO4C1 | PKM 1197/4885KMT2A 1913/4885MEN1 555/4885 |
| US-20180318217-A1 | Liposomal Curcumin for Treatment of Diseases | LIPA, LPCAT3, LCLAT1 | PKM 3022/4885KMT2A 2082/4885MEN1 255/4885 |
| US-10004687-B2 | Liposomal curcumin for treatment of diseases | LIPA, LPCAT3, LCLAT1 | PKM 3022/4885KMT2A 2082/4885MEN1 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.